单倍型相合移植规范化治疗急性白血病  

Standardized treatment of acute leukemia by haplo-identical stem cell transplantation

作　　者：马瑞 孙于谦[1] Ma Rui;Sun Yuqian(Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Diseases, Beijing 100044, China)

机构地区：[1]北京大学人民医院,北京大学血液病研究所,国家血液系统疾病临床医学研究中心,北京100044

出　　处：《临床荟萃》2021年第10期869-873,共5页Clinical Focus

摘　　要：单倍型相合移植是近年来造血干细胞移植领域内进展最为迅速的学科之一。由于单倍型移植技术体系较为复杂,目前仍主要在经验较为丰富的移植中心使用。现简要回顾单倍型相合移植治疗白血病的发展历史与现状,重点阐述单倍型相合移植“北京方案”的适应证、供者选择、移植后复发防治以及在老年等特殊患者中进行单倍型移植的诊疗策略,以期为在国内各中心更为规范的推广单倍型移植提供依据。Haplo-identical stem cell transplantation(Haplo-SCT)is one of the most rapidly developing subjects in the field of transplantation in recent years.Haplo-SCT is mainly applied in more experienced centers due to the complexity of its technics.In this review,the history and current status of Haplo-SCT in treating leukemias are summarized,and the indications,donor selection,and relapse prevention/management in the“Beijing Protocol”Haplo-SCT as well as transplant strategies in special populations including elderly people are emphatically described,with the aim of providing the basis for further standardized promotion of Haplo-SCT in domestic centers.

关 键 词：移植 半相合 白血病 急性 

分 类 号：R733.7[医药卫生—肿瘤]